Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
14q32 duplication syndrome is a rare chromosomal anomaly syndrome resulting from the partial duplication of the long arm of chromosome 14 that results in a predisposition to a number of adult-onset myeloproliferative neoplasms, including acute myeloid leukemia, chronic myelomonocytic leukemia, and myeloproliferative neoplasms, especially essential thrombocythemia. Progression to myelofibrosis and secondary acute myeloid leukemia can be observed.
Features include: Acute myeloid leukemia, Chronic myelomonocytic leukemia, and Myelofibrosis.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for 14q32 duplication syndrome.
4 publications have been identified in PubMed for 14q32 duplication syndrome. Kisho has analyzed 3 by research type. Research spans Case Report / Case Series (100%).
Panchenko E (2025). [PMID: 40943441](https://pubmed.ncbi.nlm.nih.gov/40943441/). *International journal of molecular sciences*. [Case Report / Case Series]
Chen CP (2024). [PMID: 39266159](https://pubmed.ncbi.nlm.nih.gov/39266159/). *Taiwanese journal of obstetrics & gynecology*. [Case Report / Case Series]
Lall AE (2024). [PMID: 38989381](https://pubmed.ncbi.nlm.nih.gov/38989381/). *Cureus*. [Case Report / Case Series]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 9:06 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning 14q32 duplication syndrome
Updated Feb 19, 2026
Key neurology trials are set to report data in early 2026, including the ADEPT-2 study on xanomeline/trospium for Alzheimer's psychosis and the ELEVATE-PD trial on IPX203 for Parkinson's. These studies may introduce new therapies and impact treatment strategies for Alzheimer's and Parkinson's disease.